Venanprubart

维纳扑拜单抗

Report date: 2024/07/13 20:00:08

Base Information

Drug NameVenanprubart
Drug Alias NameLY-3361237
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionB- and T-lymphocyte attenuator agonists
TargetsB- and T-lymphocyte attenuator
Therapy Area/IndicationsPsoriasisLupus Erythematosus, SystemicSjogren's Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaUnited States +[11] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSanford-Burnham Medical Research InstituteEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company
Inactive CompaniesStanford University
Active IndicationsPsoriasis
Inactive IndicationsLupus Erythematosus, SystemicSjogren's Syndrome

Other Information

ATC CodeN/A
Related LinksN/A